Clinical Study for Subjects With Osteoarthritis of Knees, Hips, and Shoulders Using a Combination of Intravenous Infusions With Intra-articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Adipose-derived autologous mesenchymal stem cell therapy-Celltex Therapeutics (Primary) ; Adipose-derived autologous mesenchymal stem cell therapy-Celltex Therapeutics (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Celltex Therapeutics
- 13 Apr 2023 Planned End Date changed from 15 Aug 2025 to 15 Aug 2026.
- 13 Apr 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 13 Apr 2023 Planned initiation date changed from 25 Sep 2022 to 25 Sep 2023.